Recent Updates
Recently added Catalysts
RDY Positive Sentiment Score: 70/100

Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompanying c

Key Takeaway: Dr. Reddy's Laboratories Limited has received a positive review from their independent registered public accounting firm regarding their interim financial statements as of December 31, 2023. The review indicated no necessary modifications for compliance with International Accounting Standard 34. Additionally, the firm's previous audit of the consolidated financial statements as of March 31, 2023, also yielded an unqualified opinion, suggesting reliability in financial reporting.

Market Sentiment Analysis

POSITIVE FACTORS

  • The review found no material modifications needed for compliance.
  • The financial statements were deemed fairly stated.
  • The audit opinion expressed was unqualified, indicating reliability.

Full Press Release Details

Report of Independent Registered Public Accounting
To the Shareholders and Board of Directors of Dr.
Reddy's Laboratories Limited
Results of Review of Interim Financial Statements
We have reviewed the accompanying condensed consolidated
interim statement of financial position of Dr. Reddy's Laboratories Limited and subsidiaries (the Company) as of December 31, 2023,
the related condensed consolidated interim income statements and statements of comprehensive income for the three and nine -month periods
ended December 31, 2023 and 2022, and the condensed consolidated interim statements of changes in equity and cash flows for the nine-month
periods ended December 31, 2023 and 2022, and the related notes (collectively referred to as the "condensed consolidated interim
financial statements"). Based on our reviews, we are not aware of any material modifications that should be made to the condensed
consolidated interim financial statements for them to be in conformity with International Accounting Standard (IAS) 34, Interim Financial
Reporting as issued by the International Accounting Standards Board.
We have previously audited, in accordance with the
standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the consolidated statement of financial
position of the Company as of March 31, 2023, the related consolidated income statements, statements of comprehensive income, changes
in equity and cash flows for the year then ended, and the related notes and schedules (not presented herein); and in our report dated
June 13, 2023, we expressed an unqualified audit opinion on those consolidated financial statements. In our opinion, the information set
forth in the accompanying condensed consolidated statement of financial position as of March 31, 2023, is fairly stated, in all material
respects, in relation to the consolidated statement of financial position from which it has been derived.
Basis for Review Results
These financial statements are the responsibility
of the Company's management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect
to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the U.S Securities and
Exchange Commission ("SEC") and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review
of interim financial statements consists principally of applying analytical procedures and making inquiries of persons responsible for
financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB,
the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express
/s/ Ernst & Young Associates LLP

Frequently Asked Questions

What financial statements did Dr. Reddy's Laboratories review?

The review included condensed consolidated interim financial statements for the periods ending December 31, 2023, and 2022.

Who conducted the review of the financial statements?

The review was performed by Ernst & Young Associates LLP, a PCAOB-registered firm.

What was the outcome of the financial review?

The review revealed no material modifications needed for compliance with IAS 34.

What type of opinion did Ernst & Young express earlier?

They expressed an unqualified audit opinion on the Company's 2023 consolidated financial statements.

What standards guided the review process?

The review was conducted according to PCAOB standards, focusing on analytical procedures.

Last updated: Jan 30, 2024